NDAORALTABLETPriority Review
Approved
Mar 2018
Lifecycle
Peak
Competitive Pressure
30/100
Mechanism of Action
Non-Nucleoside Reverse Transcriptase Inhibitors
Pharmacologic Class:
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor